STAT |
Sanofi and Regeneron encounter more payer resistance over new …
STAT Once again, Sanofi and Regeneron Pharmaceuticals are running into roadblocks trying to win over payers with their new drug for severe eczema. This time a U.K. government watchdog decided the drug would not be cost effective. Sanofi makes double EU filing for cancer and asthma drugs Sanofi responds to draft NICE guidance for its innovative atopic dermatitis drug Dupixent® ? (dupilumab)[i] Regeneron And Sanofi Say EMA Accepts For Review Application For DUPIXEN |
Tag Archives: resistance
Sanofi and Regeneron encounter more payer resistance over new … – STAT
STAT |
Sanofi and Regeneron encounter more payer resistance over new …
STAT Once again, Sanofi and Regeneron Pharmaceuticals are running into roadblocks trying to win over payers with their new drug for severe eczema. This time a U.K. government watchdog decided the drug would not be cost effective. Sanofi makes double EU filing for cancer and asthma drugs Sanofi responds to draft NICE guidance for its innovative atopic dermatitis drug Dupixent® ? (dupilumab)[i] Regeneron And Sanofi Say EMA Accepts For Review Application For DUPIXEN |
Sanofi and Regeneron encounter more payer resistance over new eczema drug — this time, in the UK – STAT
STAT |
Sanofi and Regeneron encounter more payer resistance over new eczema drug — this time, in the UK
STAT nce again, Sanofi (SNY 1) and Regeneron Pharmaceuticals (REGN 2) are running into roadblocks trying to win over payers with their new drug for severe eczema. The latest frustration is occurring in the U.K., where a government watchdog decided the drug … Sanofi makes double EU filing for cancer and asthma drugs Sanofi responds to draft NICE guidance for its innovative atopic dermatitis drug Dupixent® ? (dupilumab)[i] Regeneron And Sanofi Say EMA Accepts For Review Application For DUPIXEN |
Guided therapy can improve antibiotic resistance
Researchers share surprising findings about PCT-guided therapy in antibiotic management in patients with respiratory infections.
Managed Healthcare Executive – Health Management
Antibiotic resistance in acne: Avoid monotherapy
A recent review supports AAD and EADV calls to limit antibiotic use in acne, and to further study the issue of antimicrobial resistance.
Dermatology Times – Dermatology